Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)

被引：0
|
作者：
Zhang, H. [1 ]
Liu, L. [1 ]
Zhu, X. [1 ]
Gao, Y. [1 ]
Tong, Z. [1 ]
Fu, Q. [1 ]
Bao, X. [1 ]
Dai, X. [1 ]
Zhao, P. [1 ]
Fang, W. [1 ]
Zheng, Y. [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Oncol Dept, Sch Med, Hangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
41P
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [31] Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): First-stage results of a randomized, open-label phase II trial
    Lin, R.
    Li, H.
    Chen, X.
    Zheng, L.
    Hong, Y.
    Su, L.
    Li, C.
    Zheng, S.
    Su, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S70 - S70
  • [32] Phase II study of combination ipilimumab, nivolumab, and panitumumab in patients with KRAS, NRAS, and BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Lee, Michael
    Loehrer, Patrick
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen
    Carlson, Cheryl
    Sanoff, Hanna
    McRee, Autumn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [33] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Toshiharu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
  • [34] A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
    Ji, Dongmei
    Song, Lijie
    Cheng, Ying
    Shen, Weina
    Kuang, Muyu
    Chen, Jiaying
    Yang, Minjie
    Cui, Hongxia
    Zhou, Jinghong
    Shi, Haiyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] PRIMARY ANALYSIS OF A PHASE II, SINGLE-ARM STUDY (20060314) COMBINING PANITUMUMAB WITH FOLFIRI IN THE FIRST LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Koehne, C. H.
    Mineur, L.
    Greil, R.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    Wright, L.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2010, 21 : I51 - I51
  • [36] A phase II study of cadonilimab plus FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
    Lin, R.
    Zhao, S.
    Su, L.
    Hong, Y.
    Luo, J.
    Wei, Y.
    Zhao, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1519 - S1519
  • [37] Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
    Fakih, Marwan
    Raghav, Kanwal Pratap Singh
    Chang, David Z.
    Bendell, Johanna C.
    Larson, Timothy
    Cohn, Allen Lee
    Huyck, Timothy K.
    Cosgrove, David
    Fiorillo, Joseph A.
    Garbo, Lawrence E.
    Ravimohan, Shruthi
    Potter, Von
    D'Adamo, David
    Sharma, Neelesh
    Wang, Ying A.
    Coppieters, Sabine
    Herpers, Matthias
    de Oliveira, Carolina Soares Viana
    Paulson, Andrew Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
    Bennouna, Jaafar
    Borg, Christophe
    Delord, Jean-Pierre
    Husseini, Faress
    Trillet-Lenoir, Veronique
    Faroux, Roger
    Francois, Eric
    Ychou, Marc
    Goldwasser, Francois
    Bouche, Olivier
    Senellart, Helene
    Kraemer, Sandrine
    Douillard, Jean-Yves
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
  • [39] Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
    van den Eynde, M.
    Huyghe, N.
    Sinapi, I.
    De Cuyper, A.
    Verstraelen, E.
    Goffette, P.
    Ghaye, B.
    Papier, M.
    Bedognetti, D.
    van Maanen, A.
    Castella, M-L.
    Galon, J.
    Carrasco, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S450 - S450
  • [40] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
    He, Wen-zhuo
    Jiang, Chang
    Yi, Jiahong
    Xue, Ju
    Yin, Zhao-feng
    Dong, Wen-jing
    Xia, Liang-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345